Therabron Therapeutics Names Thomas F. Miller President and Chief Operating Officer

Company Makes Strategic Hire as it Advances a New Category of Biologic Respiratory Therapeutics

ROCKVILLE, Md.--()--Therabron Therapeutics, Inc. (Therabron), a specialty biotechnology company focused on the advancement of respiratory therapeutics with disease-modifying potential, announced that it has named Thomas F. Miller, PhD, MBA as the Company’s President and Chief Operating Officer, effective immediately. Therabron’s strategic appointment of Dr. Miller comes at a time when the Company is advancing its lead product candidate through phase 2 clinical studies and intends to advance other clinical-stage product candidates that are emerging as a result of its extensive preclinical development program. Dr. Miller will report to Dr. Aprile Pilon, Therabron’s Founder, Board Chairman, and Chief Executive Officer.

“His scientific training, relevant development background, and operational expertise within emerging biotechnology companies that were engaged in respiratory drug development will significantly compliment our existing team.”

"Therabron is poised to make significant advances in the coming months and we are very pleased that Tom has agreed to join our Executive Team," commented Dr. Pilon. “His scientific training, relevant development background, and operational expertise within emerging biotechnology companies that were engaged in respiratory drug development will significantly compliment our existing team.”

Prior to joining the company, Dr. Miller spent ten years with Discovery Laboratories, Inc., culminating in his role as the company’s Chief Operating Officer. Prior to Discovery Labs, Dr. Miller served in commercial and clinical development roles of increasing responsibility at Johnson & Johnson, Pharmacia, Novartis and Pfizer.

Dr. Miller will oversee Therabron’s operations with an initial focus on the advancement of the Company’s lead development candidate, CG100, which is currently in a phase 2 clinical trial with the goal of reducing long-term respiratory complications in premature infants. He will also oversee Therabron’s corporate development, finance and manufacturing operations.

“I am excited about the opportunity to support Therabron in this capacity, particularly because I believe that the Company’s recombinant secretoglobin platform has transformative therapeutic potential across a wide spectrum of respiratory disorders,” commented Dr. Miller. “I have a great deal of respect for the existing Executive Team and the progress they have made to date. I look forward to working with the team to advance this disruptive technology platform and contribute to building a substantial biotechnology company.”

About Therabron Therapeutics, Inc.

Therabron Therapeutics, Inc. is a clinical-stage biotechnology company, founded in 2007 and located in Rockville, MD. Therabron is focused on the advancement of respiratory therapeutics with disease-modifying potential. The company’s product candidates aim to restore the natural immune balance in the lungs of respiratory patients through the administration of recombinant human CC10 proteins. The family of CC10 proteins, also known as secretoglobins, have the potential to change the course of acute and chronic respiratory diseases, representing large markets into which few truly novel drugs have been introduced. Therabron’s product candidates have the potential to be first-in-class, disease-modifying, breakthrough biologic therapeutics. For additional information, please visit www.therabron.com.

Contacts

Therabron Therapeutics, Inc.
Media Relations
Pitch360
Michael Parks, 484-356-7105
michael@pitch360inc.com

Website